Translate this page into:
Should pyrazinamide be preferred in tuberculosis treatment during pregnancy?
*For correspondence: dr.htgozdas@yahoo.com.tr
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Sir,
We have read the recent clinical image by Garg and Mohapatra1 which is very interesting. They described a pregnant woman with tuberculosis who was treated with isoniazid, rifampicin, pyrazinamide and ethambutol for two months followed by isoniazid and rifampicin for four months. According to the current guidelines, the recommended treatment of tuberculosis in pregnancy is with isoniazid, rifampicin and ethambutol. Pyrazinamide is not recommended due to inadequate data on teratogenicity2. However, the authors detected mild intrauterine growth restriction in foetus by obstetrical ultrasound at presentation. They should clarify whether pyrazinamide is a suitable choice in tuberculosis treatment during pregnancy.
References
- A pregnant woman with dyspnoea, fever & decreased vision. Indian J Med Res. 2012;136:1062.
- [Google Scholar]
- Antimycobacterial therapy. In: Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS, eds. The Sanford guide to antimicrobial therapy (42nd ed). Sperryville, VA: Antimicrobial Therapy, Inc; 2012. p. :130.
- [Google Scholar]
